Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Common Shares
Series B preferred stock
Common Shares
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2023         $ 247
Balance (in shares) at Dec. 31, 2023         38,335
Convertible Preferred Stock          
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts         $ 386
Issuance of Series B preferred stock in connection with warrant exercise, net of discounts (in shares)         29,322
Issuance of common stock in connection with conversion of Series B preferred stock         $ (325)
Issuance of common stock in connection with conversion of Series B preferred stock (in shares)         (5,000)
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock         $ 5,842
Repurchase of Series B preferred stock and Series B preferred stock warrants         $ (6,266)
Repurchase of Series B preferred stock and Series B preferred stock warrants (in shares)         (62,657)
Balance (Accounting Standards Update 2020-06) at Mar. 31, 2024         $ 116
Balance at Dec. 31, 2023   $ 1 $ 241,884 $ (247,042) (5,157)
Balance (in shares) at Dec. 31, 2023   222,380      
Equity          
Stock-based compensation     380   380
Stock-based compensation (in shares)   4      
Issuance of common stock in connection with conversion of Series B preferred stock     325   325
Issuance of common stock in connection with conversion of Series B preferred stock (in shares)   8,038      
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock     (5,842)   (5,842)
Repurchase of Series B preferred stock and Series B preferred stock warrants     824   824
Issuance of common stock, pre-funded units and warrants, net of offering costs     4,210   4,210
Issuance of common stock, pre-funded units and warrants, net of offering costs (in shares)   1,442,518      
Issuance of common stock in connection with reverse split rounding-up for fractional shares (in shares)   84,255      
Net income (loss)       2,707 2,707
Balance (Accounting Standards Update 2020-06) at Mar. 31, 2024     (116)   (116)
Balance at Mar. 31, 2024   $ 1 241,665 (244,335) (2,669)
Balance (in shares) at Mar. 31, 2024   1,757,195      
Balance at Dec. 31, 2023         $ 247
Balance (in shares) at Dec. 31, 2023         38,335
Balance (in shares) at Dec. 31, 2024         0
Balance at Dec. 31, 2023   $ 1 241,884 (247,042) $ (5,157)
Balance (in shares) at Dec. 31, 2023   222,380      
Balance at Dec. 31, 2024   $ 5 384,172 (298,451) $ 85,726 [1]
Balance (in shares) at Dec. 31, 2024   52,034,060      
Balance (in shares) at Mar. 31, 2025         0
Equity          
Stock-based compensation     648   $ 648
Stock-based compensation (in shares)   5,986,893      
Issuance of common stock in connection with the February Offering   $ 1 4,859   $ 4,860
Issuance of common stock in connection with the February Offering (in shares)   4,757,126      
Issuance of common stock in connection with alternative cashless warrant exercise (in shares) 3,246,111       3,246,111
Conversion of liability warrants to equity warrants     15   $ 15
Net income (loss)       (9,563) (9,563)
Balance at Mar. 31, 2025   $ 6 $ 389,694 $ (308,014) $ 81,686
Balance (in shares) at Mar. 31, 2025   66,024,190      
[1] The condensed consolidated balance sheet as of December 31, 2024 was derived from the audited consolidated balance sheet as of that date.